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This systematic review aimed to examine if an association exists between dietary glycaemic index (GI) and glycaemic load (GL) intake
and breast cancer risk. A systematic search was conducted in Medline and Embase and identified 14 relevant studies up to May 2008.
Adjusted relative risk estimates comparing breast cancer risk for the highest versus the lowest category of GI/GL intake were
extracted from relevant studies and combined in meta-analyses using a random-effects model. Combined estimates from six cohort
studies show non-significant increased breast cancer risks for premenopausal women (relative risk (RR) 1.14, 95% CI 0.95–1.38) and
postmenopausal women (RR 1.11, 95% CI 0.99–1.25) consuming the highest versus the lowest category of GI intake. Evidence of
heterogeneity hindered analyses of GL and premenopausal risk, although most studies did not observe any significant association.
Pooled cohort study results indicated no association between postmenopausal risk and GL intake (RR 1.03, 95% CI 0.94–1.12).
Our findings do not provide strong support of an association between dietary GI and GL and breast cancer risk.
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Glycaemic index (GI) values classify foods according to the 2-h
blood glucose response after consuming a portion of the food
containing 50g of available carbohydrate, compared with the
equivalent amount from a standard food, such as glucose or white
bread (Jenkins et al, 1981). The glycaemic load (GL) concept was
later developed to better reflect the blood glucose response and
insulin demand of a food by taking into account the total amount
of carbohydrate usually consumed in addition to its GI value
(Salmeron et al, 1997).
Habitual consumption of a high GI or GL diet may promote
carcinogenesis by inducing hyperglycaemia and hyperinsulinaemia
(Brand-Miller, 2003), potentially acting through the insulin-like
growth factor (IGF) axis (Biddinger and Ludwig, 2005). A recent
meta-analysis illustrated that IGF-1 levels were associated with
premenopausal but not postmenopausal breast cancer risk
(Renehan et al, 2006). Additionally, high GI diets may promote
weight gain (Brand-Miller et al, 2002). High body fatness
contributes to an increased risk of postmenopausal, yet a reduced
risk of premenopausal, breast cancer (Renehan et al, 2008). There
has been a recent surge in research of the effect of GI and GL
intake on breast cancer risk; however, results to date have
been conflicting (Augustin et al, 2001; Key and Spencer, 2007;
McCann et al, 2007). This may not be surprising, given
the disparities between the biologically plausible mechanisms
suggested above.
In this systematic review, we had the aim of clarifying any
association between dietary GI, GL and breast cancer risk, and of
determining if risk varies according to menopausal status or body
fatness.
MATERIALS AND METHODS
Ovid Medline, including Medline In-Process (US National Library
of Medicine, Bethesda, MD, USA), and Embase (Reed Elsevier PLC,
Amsterdam, Netherlands) databases were systematically searched
for relevant studies published up to May 2008. The search strategy
incorporated various medical search heading terms and keywords
for GI, GL, nutrition and cancer. Animal studies were excluded but
no language restrictions were imposed. The inclusion criteria
included both cohort and case–control studies that had assessed
dietary GI and/or GL intake in their study population and reported
adequate information regarding cancer incidence, including
relative risk (RR) estimates and corresponding 95% confidence
intervals (CIs).
Two independent reviewers (HGM, MMC) screened studies for
inclusion by examining abstracts and then full text where
necessary, with discrepancies resolved by discussion. The refer-
ence lists of all included studies were also searched. The reviewers
extracted information on study design, population characteristics,
exclusion criteria, dietary assessment of GI and GL, adjustments
for confounders and results from each study. The Newcastle-
Ottawa quality assessment scale (www.lri.ca) was applied to all
studies to consider factors such as selection of participants,
comparability of studies, follow-up and ascertainment of exposure
and outcome.
Meta-analyses were conducted using studies that compared
categories of GI or GL intake to produce risk estimates and
presented results separately by menopausal status. Studies
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ycategorised intake by quartiles (McCann et al, 2007; Sieri et al,
2007; Lajous et al, 2008) or quintiles (Augustin et al, 2001; Cho
et al, 2003; Jonas et al, 2003; Frazier et al, 2004; Higginbotham
et al, 2004; Holmes et al, 2004; Lajous et al, 2005; Silvera et al,
2005). Two studies could not be included in meta-analyses, as
GI/GL intakes were only examined as continuous variables
(Nielsen et al, 2005; Giles et al, 2006), and another study was
excluded, as it did not present results separately by menopausal
status (Levi et al, 2002). Adjusted RR estimates and 95% CI
comparing the highest versus the lowest category of GI and GL
intake were combined and weighted using a random-effects model.
Sensitivity analysis was performed for cohort and case–control
studies separately, premenopausal versus postmenopausal women,
by body mass index (BMI) categories where possible, by dietary
assessment methods used, by GI/GL values, by follow-up time for
cohort studies, by quality scale score, by geographic variations and
by systematically removing each individual study. Heterogeneity in
each meta-analysis was investigated using the w
2 test and I
2
statistic. Funnel plots of study relative risks plotted against their
corresponding standard errors were assessed for asymmetry to test
for publication bias. Statistical analysis was conducted using
Intercooled STATA version 9.2 (StataCorp 2005, College Station,
TX, USA).
RESULTS
The electronic database searches identified 464 publications, and 2
independent reviewers screened abstracts, titles then full text to
select 51 articles, which were relevant for data extraction on GI, GL
and risk of all cancers. Four articles were multiple publications
from the same study and one further article did not provide
sufficient information on their results, and hence were excluded.
Of the remaining studies, 14 specifically referred to breast cancer
risk (Augustin et al, 2001; Levi et al, 2002; Cho et al, 2003; Jonas
et al, 2003; Frazier et al, 2004; Higginbotham et al, 2004; Holmes
et al, 2004; Lajous et al, 2005, 2008; Nielsen et al, 2005; Silvera et al,
2005; Giles et al, 2006; McCann et al, 2007; Sieri et al, 2007), the
characteristics of which are summarised in Table 1. Cohort studies
accounted for 10, one of which was a retrospective design, and the
remaining 4 publications were case–control studies. Eight studies
originated from North and Central America, five from Europe and
one from Australia.
Cohort studies scored more highly on the quality scale
compared with population-based case–control studies, which in
turn ranked higher than hospital-based case–control studies
(Table 1). In case–control studies, cases were identified by
histological confirmation, whereas cohort studies identified cases
through linkage to cancer registries, self-report, medical record
review or a combination of these methods. Food Frequency
Questionnaires (FFQs) were used in all studies to assess habitual
dietary intake, and two cohorts repeated dietary assessment at
multiple time points and subsequently were able to calculate
cumulative average GI/GL intakes (Cho et al, 2003; Holmes et al,
2004). Most studies sourced GI and GL values from International
Tables (Foster-Powell and Miller, 1995; Foster-Powell et al, 2002),
with the exception of Sieri et al (2007), who primarily used GI and
GL values calculated from their local Italian foods. The majority of
studies included age, BMI and energy intake in their adjusted
analysis and all that were included in meta-analyses adjusted for
women’s reproductive and menstrual histories (Table 1). In
addition, only two studies controlled for history of diabetes among
breast cancer cases (Augustin et al, 2001; Jonas et al, 2003).
There was evidence of marked heterogeneity in analyses of
GI/GL intake and breast cancer risk when all studies were
combined and therefore analyses were restricted to cohort studies
only. As shown in Figure 1, there was some evidence of an
association between the highest versus the lowest category of GI
intake and premenopausal (RR 1.14, 95% CI 0.95–1.38) and
postmenopausal (RR 1.11, 95% CI 0.99–1.25) risk when six cohort
study results were combined; however, these did not reach
statistical significance. Although not statistically significant,
moderate heterogeneity was still observed, which was not reduced
when studies were grouped by differences in their quality scale
score, cohort follow-up time, geographic variations or median
GI/GL values. When analysis was restricted to cohort studies
that had incorporated a more robust measure of dietary intake,
that is, X100-item FFQ, heterogeneity was somewhat reduced
and a significant association emerged between GI intake and
premenopausal (RR 1.20, 95% CI 1.01–1.43, I
2¼37%, P¼0.17)
and postmenopausal risk (RR 1.10 95% CI 1.02–1.19, I
2¼0%,
P¼0.46). Significant heterogeneity was observed when the results
of case–control studies examining premenopausal (I
2¼64%,
P¼0.05) or postmenopausal risk (I
2¼83%, Po0.01) were
combined and so the pooled estimate is not presented. However,
only the hospital-based case–control study demonstrated a
positive association between GI intake and breast cancer risk.
None of the studies that were excluded from our meta-analyses
demonstrated an association with GI intake, two of which were
conducted in postmenopausal women and one that combined
premenopausal and postmenopausal women (Levi et al, 2002;
Nielsen et al, 2005; Giles et al, 2006).
There was a lack of symmetry in the funnel plot of GL and
premenopausal breast cancer, the results indicating possible
publication bias. As shown in Figure 2, most studies did not
demonstrate any evidence of an association between the highest
versus the lowest category of GL intake and premenopausal risk,
with one notable exception (Sieri et al, 2007). There was evidence
of heterogeneity when combining cohort studies (I
2¼69%,
Po0.01), and therefore no combined risk estimate is presented,
but removing the study by Sieri et al revealed no association
between GL and premenopausal risk (RR 1.02, 95% CI 0.89–1.16,
I
2¼9%, P¼0.35). Combining data from cohort studies demon-
strated no evidence of an association between postmenopausal risk
in the highest GL consumers (RR 1.03, 95% CI 0.94–1.12).
Significant heterogeneity was incorporated when combining case–
control studies, and therefore no combined estimate is presented,
although results from these were inconsistent. Two studies
examined GL as continuous variables but did not identify any
significant association with breast cancer risk (Nielsen et al, 2005;
Giles et al, 2006).
Five studies presented GI, GL and breast cancer risk results
stratified by BMI categories (Cho et al, 2003; Holmes et al, 2004;
Silvera et al, 2005; McCann et al, 2007) and the observed
associations did not differ when these were combined separately
for normal weight or overweight women (data not shown).
DISCUSSION
This systematic review and meta-analyses of GI and GL intake and
breast cancer risk is the most comprehensive to date and the first to
examine the association by menopausal status. Overall, we did not
find any strong association between these dietary carbohydrate
measures in relation to either premenopausal or postmenopausal risk.
Although no significant association was observed between the
highest versus the lowest category of GI intake and breast cancer
risk, positive associations became apparent once analysis was
restricted to cohort studies utilising a more robust measure of
dietary intake, that is, X100-item FFQs. However, in our
systematic review, we performed many stratified analyses to
reduce statistical heterogeneity, and therefore any associations
shown could have been due to chance. Furthermore, most studies
that were not included in our meta-analysis did not observe
significant associations with GI (Nielsen et al, 2005; Giles et al,
2006).
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yTable 1 Characteristics of studies included in systematic review of dietary glycaemic index, glycaemic load and risk of breast cancer
Adjusted confounders
Authors (date),
location Study
Study design
(mean follow-up) Cases
Controls/
cohort
size
Diet
assessment
Quality
scale
score
Median GI
(IQ range)
Median GL
(IQ range) Age BMI Energy Hormon. Reprod. Menstr. Smoking PA Education Alcohol Family BBD
Lajous et al
(2008), France
E3N Study Prospective
cohort (9 years)
a
1812 62739 Self-reported
208-item FFQ
9/9 55 (44–66) 123 (84–165) | | || || | | | | |
Sieri et al
(2007), Italy
ORDET Study Prospective
cohort (11.5 years)
289 8959 Self-reported
107-item FFQ
8/9 56 (52–59) 113 (97–151) | | || ||| | |
McCann et al
(2007), USA
WEB Study Population-based
case–control
1166 2105 Interviewed
FFQ
7/9 77 (70–83)
b 147 (104–186)
b || | | | | | |
Giles et al
(2006),
Australia
Melbourne
Collaborative
Cohort Study
Prospective
cohort
(9.1 years)
324 12273 Self-reported
121-item FFQ
9/9 49 (46–53) 108 (77–150) | # || ## # # # #
Nielsen et al
(2005), Denmark
Diet, Cancer &
Health Cohort
Prospective
cohort (6.6 years)
634 23870 Self-reported
192-item FFQ
9/9 — — || | | | |
Silvera et al
(2005), Canada
National Breast
Screening Study
Prospective
cohort (16.6 years)
2518 49111 Self-reported
86-item FFQ
9/9 77 (60–96) 104 (83–123) | | || || | | |
Lajous et al
(2005), Mexico
Population-based
case–control
475 1391 Interviewed
FFQ
7/9 62 (—) 152 (44–214) || | | | |
Higginbotham
et al (2004), USA
Women’s Health
Study
Prospective cohort
(6.8 years)
946 38446 Self-reported
131-item FFQ
9/9 53 (50–55) 117 (92–143) | | || ||| | | |
Holmes et al
(2004), USA
Nurses’ Health
Study
Prospective
cohort (18 years)
4092 88678 Multiple
self-reported
61+ item FFQs
8/9 75 (69–81) 105 (81–130) || | | | | | |
Frazier et al
(2004), USA
Nurses’ Health
Study II
Retrospective
cohort
361 47355 Self-reported
131-item FFQ
8/9 79 (74–84) 170 (141–202) | | || || | | |
Cho et al
(2003), USA
Nurses’ Health
Study II
Prospective
cohort (8 years)
a
714 90655 Self-reported
133-item FFQ
142-item FFQ
8/9 77 (70–82) 120 (97–148) | | || ||| | | |
Jonas et al
(2003), USA
CPS II Nutrition
Cohort
Prospective
cohort (5 years)
1442 63307 Self-reported
68-item FFQ
8/9 74 (65–85) 81 (58–103) | | || ||| | | | | |
Levi et al (2002),
Switzerland
Hospital-based
case–control
331 534 Interviewed
79-item FFQ
6/9 92 (73–112) — || | | | | | |
Augustin et al
(2001), Italy
Hospital-based
case–control
2569 2588 Interviewed
78-item FFQ
6/9 74 (70–79) 132 (98–174) || | | | | | |
CPS¼Cancer Prevention Study; E3N¼French component of European Prospective Investigation into Diet and Cancer Study; ORDET¼Hormones and Diet in Etiology of Breast Tumors Study; WEB¼Western New York
Exposure and Breast Cancer Study.
aTotal follow-up length, mean not reported.
bPostmenopausal GI/GL data; majority of study participants (60–70%) are postmenopausal. Adjusted confounders: age; BMI¼body mass index or
body weight; energy¼energy intake; hormon.¼hormone replacement therapy/oral contraceptive use; reprod.¼reproductive factors (e.g., parity, age at first birth); menstr.¼menstrual history (e.g., age at menarche or menopause,
menopausal status); smoking; PA¼physical activity; education; alcohol¼alcohol intake; family¼family history of breast cancer; BBD¼history of benign breast disease.
# confounder tested but not included in final model.
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yThere was some evidence of publication bias when examining
funnel plots of GL and premenopausal breast cancer risk, although
the majority of studies reported no significant associations. Our
findings also provided little evidence of an association between GL
intake and postmenopausal risk. A recent meta-analysis of 20
studies demonstrated a 1.2-fold increase in risk for women with
Study  Relative risk 
(95% CI) 
Relative 
weight (%) 
Premenopausal
Cohorts 
Sieri 2007  1.82 (1.01–3.27)  8 
Silvera 2005  0.78 (0.52–1.16)  14 
Higginbotham 2004  1.29 (0.92–1.81)  17 
Holmes 2004  1.02 (0.82–1.28)  23 
Frazier 2004  1.47 (1.04–2.08)  16 
Cho 2003  1.05 (0.83–1.33)  22 
1.14 (0.95–1.38)*  100
Case–control
McCann 2007  1.02 (0.68–1.53) 
Lajous 2005  0.66 (0.39–1.12) 
Augustin 2001  1.37 (1.00–1.89) 
*Test for heterogeneity 
2= 9.9, d.f.= 5, P=0.08; I
2  =49% (95% CI 0–80%)
Postmenopausal
Cohorts 
Lajous 2008  1.14 (0.99–1.32)  26 
Sieri 2007  1.12 (0.62–2.02)  4 
Silvera 2005  1.87 (1.18–2.97)   5 
Higginbotham 2004  0.89 (0.67–1.17)  12 
Holmes 2004  1.15 (1.02–1.30)  30 
Jonas 2003  1.03 (0.87–1.22)  23 
1.11 (0.99–1.25)*  100
Case–control
McCann 2007  0.80 (0.61–1.03) 
Lajous 2005  0.81 (0.54–1.22) 
Augustin 2001  1.40 (1.12–1.75) 
                                                 *Test for heterogeneity 
2= 8.6, d.f.= 5, P=0.12; I
2 =42% (95% CI 0–77%)
0.5    0.66          1           1.5       2    2.5   3 
Figure 1 Forest plot of highest versus lowest category of GI intake and breast cancer risk. Bold relative risks denote combined effect estimates.
Study  Relative risk 
(95% CI) 
Relative 
weight (%) 
Premenopausal
Cohorts 
Sieri 2007  3.89 (1.81–8.34) 
Silvera 2005  0.96 (0.76–1.22) 
Higginbotham 2004  1.27 (0.79–2.03) 
Holmes 2004  0.87 (0.70–1.12) 
Frazier 2004  1.23 (0.91–1.67) 
Cho 2003  1.06 (0.78–1.45) 
Case–control
McCann 2007  1.01 (0.60–1.72) 
Lajous 2005  1.43 (0.81–2.53) 
Augustin 2001  1.24 (0.90–1.70) 
Postmenopausal
Cohorts 
Lajous 2008  1.11 (0.96–1.29) 28 
Sieri 2007  1.67 (0.80–3.46) 1 
Silvera 2005  1.08 (0.82–1.41) 10 
Higginbotham 2004  0.90 (0.63–1.31) 6 
Holmes 2004  1.03 (0.90–1.16) 34 
Jonas 2003  0.90 (0.76–1.08) 21 
1.03 (0.94–1.12)*  100
Case–control
McCann 2007  0.74 (0.53–1.03) 
Lajous 2005  2.18 (1.34–3.55) 
Augustin 2001  1.46 (1.15–1.86) 
                               *Test for heterogeneity 
2= 5.5, d.f.= 5, P=0.34; I
2 =12% (95% CI 0–78%)
 1       0.5  0.66     1.5    2  2.5 3
Figure 2 Forest plot of highest versus lowest category of GL intake and breast cancer risk. Bold relative risks denote combined effect estimates.
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linaemia may be a contributory factor in breast cancer. However, if
risk is related to the overall insulin demand of the diet, stronger
associations would be expected for GL rather than GI (Key, 2001)
and we observed no association between GL and breast cancer risk.
Additionally, C-peptide, a marker of insulin secretion, was not
found to be related to risk in two well-designed cohort studies
(Verheus et al, 2006; Eliassen et al, 2007), and so there is little
evidence to support a direct association between insulin and breast
carcinogenesis.
It has been hypothesised that chronic hyperinsulinaemia
induced by a high GI diet may suppress fat oxidation and promote
carbohydrate oxidation in the body, resulting in an enhanced
appetite and body fat gain (Brand-Miller et al, 2002). We did not
observe any association between GI/GL intake and breast cancer
risk by BMI categories in our limited analysis. However, only five
studies reported risk by BMI and none of these were powered to
include obese women as a separate subgroup (Cho et al, 2003;
Holmes et al, 2004; Silvera et al, 2005; McCann et al, 2007), there-
fore further research is warranted in this population subgroup.
It is possible that dietary measurement error associated with
FFQs may have attenuated any real association between GI, GL and
breast cancer risk. The FFQs used were quite variable in length,
ranging from 61 items to 192 items in length and only two studies
incorporated repeat dietary assessments at different time points to
account for potential changes in dietary habits during the follow-
up period (Cho et al, 2003; Holmes et al, 2004). Importantly,
individual studies reported in this review collected information
about menopausal status only at baseline, which after long follow-
up periods, for example, in the Canadian Breast Screening Study
and the US Nurses Health Study (Holmes et al, 2004; Silvera et al,
2005), are likely to be inaccurate at the time of analysis. Future
studies should ideally collect information on BMI and menopausal
status at multiple time points during follow-up periods.
Our meta-analysis has limitations; for example, the study results
were inconsistently adjusted for potential confounders (e.g.,
history of diabetes), which might result in residual confounding.
Each study in the meta-analyses had categorised GI and GL intake
differently, and utilised a mixture of glucose and white bread
reference values. Therefore, we assessed risk in the highest
compared with the lowest category of intake, although absolute
GI and GL intake within these categories differed between studies,
which is not ideal. A relatively small number of studies were
included in our analyses, particularly for subgroup analysis, which
made it difficult to estimate publication bias and heterogeneity.
Nevertheless this meta-analysis achieved reasonable statistical
power. In conclusion, our systematic review suggests that high
dietary GI and GL intakes do not appear to be of aetiological
importance in breast tumour development.
ACKNOWLEDGEMENTS
We acknowledge Ms Alex McIlroy for her assistance in developing
the electronic search strategy used in the systematic review. HG
Mulholland is funded by a PhD studentship from the Department
for Employment and Learning, UK.
REFERENCES
Augustin LS, Dal Maso L, La Vecchia C, Parpinel M, Negri E, Vaccarella S,
Kendall CW, Jenkins DJ, Franceschi S (2001) Dietary glycemic index and
glycemic load, and breast cancer risk: a case–control study. Ann Oncol
12: 1533–1538
Biddinger SB, Ludwig DS (2005) The insulin-like growth factor axis: a
potential link between glycemic index and cancer. Am J Clin Nutr 82:
277–278, doi:82/2/277
Brand-Miller JC (2003) Glycemic load and chronic disease. Nutr Rev 61:
S49–S55
Brand-Miller JC, Holt SH, Pawlak DB, McMillan J (2002) Glycemic index
and obesity. Am J Clin Nutr 76: S281–S285
Cho E, Spiegelman D, Hunter DJ, Chen WY, Colditz GA, Willett WC (2003)
Premenopausal dietary carbohydrate, glycemic index, glycemic load, and
fiber in relation to risk of breast cancer. Cancer Epidemiol Biomarkers
Prev 12: 1153–1158
Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN, Hankinson SE (2007)
Circulating insulin and c-peptide levels and risk of breast cancer among
predominately premenopausal women. Cancer Epidemiol Biomarkers
Prev 16: 161–164, doi:10.1158/1055-9965
Foster-Powell K, Holt SH, Brand-Miller JC (2002) International table of
glycemic index and glycemic load values: 2002. Am J Clin Nutr 76: 5–56
Foster-Powell K, Miller JB (1995) International tables of glycemic index.
Am J Clin Nutr 62: S871–S890
Frazier AL, Li L, Cho E, Willett WC, Colditz GA (2004) Adolescent diet and
risk of breast cancer. Cancer Causes Control 15: 73–82, doi:10.1023/
B:CACO.0000016617.57120
Giles GG, Simpson JA, English DR, Hodge AM, Gertig DM, Macinnis RJ,
Hopper JL (2006) Dietary carbohydrate, fibre, glycaemic index,
glycaemic load and the risk of postmenopausal breast cancer. Int J
Cancer 118: 1843–1847, doi:10.1002/ijc.21548
Higginbotham S, Zhang ZF, Lee IM, Cook NR, Buring JE, Liu S (2004)
Dietary glycemic load and breast cancer risk in the Women’s Health
Study. Cancer Epidemiol Biomarkers Prev 13: 65–70
Holmes MD, Liu S, Hankinson SE, Colditz GA, Hunter DJ, Willett WC
(2004) Dietary carbohydrates, fiber, and breast cancer risk. Am J
Epidemiol 159: 732–739
Jenkins DJ, Wolever TM, Taylor RH, Barker H, Fielden H, Baldwin JM,
Bowling AC, Newman HC, Jenkins AL, Goff DV (1981) Glycemic index of
foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr
34: 362–366
Jonas CR, McCullough ML, Teras LR, Walker-Thurmond KA, Thun MJ,
Calle EE (2003) Dietary glycemic index, glycemic load, and risk of
incident breast cancer in postmenopausal women. Cancer Epidemiol
Biomarkers Prev 12: 573–577
Key TJ (2001) Glycemic index, hyperinsulinemia, and breast cancer risk.
Ann Oncol 12: 1507–1509
Key TJ, Spencer EA (2007) Carbohydrates and cancer: an overview of the
epidemiological evidence. Eur J Clin Nutr 61(Suppl 1): S112–S121,
doi:10.1038/sj.ejcn.1602941
Lajous M, Boutron-Ruault MC, Fabre A, Clavel-Chapelon F, Romieu I
(2008) Carbohydrate intake, glycemic index, glycemic load, and risk of
postmenopausal breast cancer in a prospective study of French women.
Am J Clin Nutr 87: 1384–1391
Lajous M, Willett W, Lazcano-Ponce E, Sanchez-Zamorano LM, Hernan-
dez-Avila M, Romieu I (2005) Glycemic load, glycemic index, and the
risk of breast cancer among Mexican women. Cancer Causes Control 16:
1165–1169, doi:10.1007/s10552-005-0355-x
Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of
breast cancer: a meta-analysis. Int J Cancer 121: 856–862, doi:10.1002/
ijc.22717
Levi F, Pasche C, Lucchini F, Bosetti C, La Vecchia C (2002) Glycaemic
index, breast and colorectal cancer. Ann Oncol 13: 1688–1689
McCann SE, McCann WE, Hong CC, Marshall JR, Edge SB, Trevisan M,
Muti P, Freudenheim JL (2007) Dietary patterns related to glycemic
index and load and risk of premenopausal and postmenopausal breast
cancer in the Western New York Exposure and Breast Cancer Study.
Am J Clin Nutr 86: 465–471
Nielsen TG, Olsen A, Christensen J, Overvad K, Tjonneland A (2005)
Dietary carbohydrate intake is not associated with the breast cancer
incidence rate ratio in postmenopausal Danish women. J Nutr 135:
124–128, doi:135/1/124
Renehan AG, Harvie M, Howell A (2006) Insulin-like growth factor (IGF)-I,
IGF binding protein-3, and breast cancer risk: eight years on. Endocr
Relat Cancer 13: 273–278, doi:10.1677/erc.1.01219
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass
index and incidence of cancer: a systematic review and meta-analysis of
GI, GL and breast cancer risk
HG Mulholland et al
1174
British Journal of Cancer (2008) 99(7), 1170–1175 & 2008 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yprospective observational studies. Lancet 371: 569–578, doi:10.1016/
S0140-6736(08)60269-X
Salmeron J, Ascherio A, Rimm EB, Colditz GA, Spiegelman D, Jenkins DJ,
Stampfer MJ, Wing AL, Willett WC (1997) Dietary fiber, glycemic load,
and risk of NIDDM in men. Diabetes Care 20: 545–550
Sieri S, Pala V, Brighenti F, Pellegrini N, Muti P, Micheli A, Evangelista A,
Grioni S, Contiero P, Berrino F, Krogh V (2007) Dietary glycemic index,
glycemic load, and the risk of breast cancer in an Italian prospective
cohort study. Am J Clin Nutr 86: 1160–1166
Silvera SA, Jain M, Howe GR, Miller AB, Rohan TE (2005) Dietary
carbohydrates and breast cancer risk: a prospective study of the roles of
overall glycemic index and glycemic load. Int J Cancer 114: 653–658,
doi:10.1002/ijc.20796
Verheus M, Peeters PH, Rinaldi S, Dossus L, Biessy C, Olsen A, Tjonneland A,
Overvad K, Jeppesen M, Clavel-Chapelon F, Tehard B, Nagel G, Linseisen J,
Boeing H, Lahmann PH, Arvaniti A, Psaltopoulou T, Trichopoulou A, Palli
D, Tumino R, Panico S, Sacerdote C, Sieri S, van Gils CH, Bueno-de-
Mesquita BH, Gonzalez CA, Ardanaz E, Larranaga N, Garcia CM, Navarro
C, Quiros JR, Key T, Allen N, Bingham S, Khaw KT, Slimani N, Riboli E,
Kaaks R (2006) Serum C-peptide levels and breast cancer risk: results from
the European Prospective Investigation into Cancer and Nutrition (EPIC).
Int J Cancer 119: 659–667, doi:10.1002/ijc.21861
GI, GL and breast cancer risk
HG Mulholland et al
1175
British Journal of Cancer (2008) 99(7), 1170–1175 & 2008 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
y